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Abstract: BACKGROUND: Depression is associated with major patient burden. Its treatment requires
complex and collaborative approaches. A stepped care model based on the German National Clinical
Practice Guideline ”Unipolar Depression” has been shown to be effective. In this study we assess the
cost-effectiveness of this guideline based stepped care model versus treatment as usual in depression.
METHODS: This prospective cluster-randomized controlled trial included 737 depressive adult patients.
Primary care practices were randomized to an intervention (IG) or a control group (CG). The intervention
consisted of a four-level stepped care model. The CG received treatment as usual. A cost-utility analysis
from the societal perspective with a time horizon of 12 months was performed. We used quality-adjusted
life years (QALY) based on the EQ-5D-3L as effect measure. Resource utilization was assessed by patient
questionnaires. Missing values were imputed by ’multiple imputation using chained equations’ based on
predictive mean matching. We calculated adjusted group differences in costs and effects as well as in-
cremental cost-effectiveness ratios. To describe the statistical and decision uncertainty cost-effectiveness
acceptability curves were constructed based on net-benefit regressions with bootstrapped standard errors
(1000 replications). The complete sample and subgroups based on depression severity were considered.
RESULTS: We found no statically significant differences in costs and effects between IG and CG. The
incremental total societal costs (+€5016; 95%-CI: [-€259;€10,290) and effects (+ 0.008 QALY; 95%-CI:
[- 0.030; 0.046]) were higher in the IG in comparison to the CG. Significantly higher costs were found
in the IG for outpatient physician services and psychiatrist services in comparison to the CG. Signifi-
cantly higher total costs and productivity losses in the IG in comparison to the CG were found in the
group with severe depression. Incremental cost-effectiveness ratios for the IG in comparison to the CG
were unfavourable (complete sample: €627.000/QALY gained; mild depression: dominated; moderately
severe depression: €645.154/QALY gained; severe depression: €2082,714/QALY gained) and the prob-
ability of cost-effectiveness of the intervention was low, except for the group with moderate depression
(ICER: dominance; 70% for willingness-to-pay threshold of €50,000/QALY gained). CONCLUSIONS We
found no evidence for cost-effectiveness of the intervention in comparison to treatment as usual. TRIAL
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Abstract
Background: Depression is associated with major patient burden. Its treatment requires complex and collaborative
approaches. A stepped care model based on the German National Clinical Practice Guideline “Unipolar Depression”
has been shown to be effective. In this study we assess the cost-effectiveness of this guideline based stepped care
model versus treatment as usual in depression.
Methods: This prospective cluster-randomized controlled trial included 737 depressive adult patients. Primary care
practices were randomized to an intervention (IG) or a control group (CG). The intervention consisted of a four-level
stepped care model. The CG received treatment as usual. A cost-utility analysis from the societal perspective with a
time horizon of 12months was performed. We used quality-adjusted life years (QALY) based on the EQ-5D-3L as effect
measure. Resource utilization was assessed by patient questionnaires. Missing values were imputed by ‘multiple
imputation using chained equations’ based on predictive mean matching. We calculated adjusted group differences in
costs and effects as well as incremental cost-effectiveness ratios. To describe the statistical and decision uncertainty
cost-effectiveness acceptability curves were constructed based on net-benefit regressions with bootstrapped standard
errors (1000 replications). The complete sample and subgroups based on depression severity were considered.
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Results: We found no statically significant differences in costs and effects between IG and CG. The incremental total
societal costs (+€5016; 95%-CI: [−€259;€10,290) and effects (+ 0.008 QALY; 95%-CI: [− 0.030; 0.046]) were higher in the IG
in comparison to the CG. Significantly higher costs were found in the IG for outpatient physician services and
psychiatrist services in comparison to the CG. Significantly higher total costs and productivity losses in the IG in
comparison to the CG were found in the group with severe depression. Incremental cost-effectiveness ratios for the IG
in comparison to the CG were unfavourable (complete sample: €627.000/QALY gained; mild depression: dominated;
moderately severe depression: €645.154/QALY gained; severe depression: €2082,714/QALY gained) and the probability
of cost-effectiveness of the intervention was low, except for the group with moderate depression (ICER: dominance;
70% for willingness-to-pay threshold of €50,000/QALY gained).
Conclusions: We found no evidence for cost-effectiveness of the intervention in comparison to treatment as usual.
Trial registration: NCT, NCT01731717. Registered 22 November 2012 - Retrospectively registered.
Keywords: Depressive disorder, Costs and cost analysis, Quality-adjusted life years, Delivery of healthcare, integrated
Background
Depression affects society in different ways. The preva-
lence of depression is high [1], diagnosis is made and
treatment initiated with a major delay [2–4], it is associ-
ated with a substantial disease burden in terms of loss of
quality of life [5], worsens the course and prognosis of
somatic diseases [6–8] and causes a high economic bur-
den [9]. These challenges have been addressed by the
development of systematic care approaches. In Germany,
the National Clinical Practice Guideline “Unipolar De-
pression” [10, 11] recommends a stepped care approach
based on collaborative principles [10]. The aim of
stepped care is the supply of treatment at the least ne-
cessary intensity while constantly monitoring the course
of disease [12].
Programs based on the stepped care approach have
already been implemented and evaluated in different
contexts. Systematic reviews conclude that stepped
care could be at least as effective as usual care [13].
However, further need for research, e.g. into the spe-
cific characteristics of stepped services, the preferred
model of delivery or the implementation of stepped
care programs, is identified by these reviews [13, 14].
Considering the cost-effectiveness, there is evidence
from several studies. However, most of these studies
took a rather specific focus on stepped care ap-
proaches by evaluating the inclusion of digital mea-
sures into stepped care models [15–18] or by
investigating stepped care in populations with specific
underlying diseases [19–21] or in combination with
other interventions [22, 23] or in specific populations
[24–30]. There are three studies that show a certain
degree of comparability to our study by evaluating
stepped care exclusively for depression in a primary
care sample. The study by Simon et al. is the least
comparable study of those [31]. The authors of this
study, who found that stepped care leads to substan-
tially improved health with moderately increased
costs, included only patients with depression persist-
ent after 6–8 weeks of antidepressant treatment. This
definition excludes huge numbers of patients and
limits comparability to studies with broader inclusion
criteria. A broader definition for inclusion was
employed by Yan et al., who evaluated a stepped care
treatment program compared to different usual care
approaches. They found no clinical differences in
health outcomes between the comparison groups [32].
However, they also identified potential cost savings.
The study with the highest degree of comparability is
the study by Meeuwissen et al., who assessed a
stepped care programme based on a national treat-
ment guideline [33]. They conducted a model-based
economic evaluation of a stepped care program based
on the Dutch guidelines. They found that this pro-
gram is cost-effective compared to usual care.
To assess the effectiveness and cost-effectiveness of the
German National Clinical Practice Guideline we transferred
its recommendations into a program for clinical practice.
The results of the effectiveness assessment have already
been published [34]. The intervention, a guideline-based
stepped care model (SCM), showed significantly higher
odds of remission and response as well as a significant re-
duction of depression severity in comparison to the CG
which received treatment as usual (TAU) [34]. However,
the effectiveness assessment did not include the economic
consequences of the intervention. While the assessment of
effectiveness takes the benefit for patients into account, the
assessment of economic consequences considers a wider
perspective and provides evidence on the societal benefits
by putting the health benefits into context to the costs
caused by achieving these benefits. This supports policy
makers in making informed decisions on the allocation of
scarce healthcare resources. To provide this evidence, we
performed a cost-effectiveness analysis comparing SCM
and TAU in patients with depression over the course of 1
year from the perspective of the German society.
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Methods
Sample
The details of this study (ClinicalTrials.gov: NCT01731717)
have been reported elsewhere [35]. In summary, this ana-
lysis is based on a prospective cluster-randomized con-
trolled trial. The intervention group (IG) was treated in the
SCM. The control group (CG) received TAU. The treat-
ments are described in detail below. Patient recruitment
and inclusion was performed between August 2012 and
March 2014 in 49 (IG: 36; CG: 13) primary care practices
in Hamburg, Germany (Follow-ups: between 2012 and
April 2015). The randomization process was not blinded
and took place on the practice level. Randomization was
performed by a computer program (minimisation based on
location and size of practices and the income level of the
district the practice is located in). The randomization
scheme between IG and CG was 3:1. Patients were included
if they had a score ≥ 5 on the Patient Health Questionnaire-
(PHQ-) 9 (indicating a mild depression at minimum), were
18 years or older and gave informed consent. Patients were
excluded if they had insufficient German language skills or
if a disease or disorder made it impossible to complete the
questionnaire. Additionally, patients were excluded if their
main treatment focus was on a comorbid mental disorder
and not on depression.
Interventions
IG (SCM)
Patients in the IG received services from a stratified stepped
and collaborative care program, including GP, psychiatrists,
psychotherapists and psychiatric inpatient facilities. The
intervention consisted of four steps. Step 1 incorporated ac-
tive monitoring, Step 2 bibliotherapy, internet-based self-
management and telephone-administered psychotherapy.
Step 3 consisted of outpatient psychotherapy or antidepres-
sant pharmacotherapy. In Step 4, a combination of psycho-
and pharmacotherapy in an out- or inpatient setting was
performed. The GP allocated the different interventions ac-
cording to the guideline recommendations considering de-
pression severity and patient preferences (shared decision
making). For the initial depression treatment, patients re-
ceived a specified depression diagnosis based on the ICD-
10 criteria as recommended in the National Clinical Prac-
tice Guideline. This included information on subtype and
disease severity. Monitoring and treatment adaption was
performed based on the assessment of the PHQ-9 in regu-
lar intervals. A stepping up of treatment intensity was rec-
ommended in case that depression severity had not
improved by at least 20% since the last contact. Addition-
ally, an online platform displaying vacant treatment capaci-
ties in secondary care, a provider network, intensive
training of GP regarding guideline recommendations and
quarter-yearly quality circles were introduced.
CG (tau)
A diagnosis based on the ICD-10 criteria was not deter-
mined for patients in the CG. These patients were able
to receive every approved treatment. This includes out-
patient as well as inpatient psychotherapeutic or psychi-
atric services. GP in the CG had no access to the online
platform, the provider network, the training regarding
guideline recommendations or the quarter-yearly quality
circles.
Data collection and measures
Data collection
Data were collected at four time points by means of self-
reported questionnaires which were returned by mail:
baseline (T0), after 3 months (T1), after 6 months (T2)
and after 12 months (T3). Accordingly, the time horizon
of the study was 1 year.
We assessed sociodemographic information, type of
health insurance, employment status, social support (F-
SOZU-14 [36]), the symptom severity of depression
(PHQ-9 [37, 38]) and the physical and mental health sta-
tus (Physical Component Score (PCS) and Mental Com-
ponent Score (MCS) of the Short-Form-12 (SF-12) [39–
41]). Main outcomes of the cost-effectiveness analysis
were quality-adjusted life years (QALY) in the 12-month
period between T0 and T3 (EQ-5D-3L as measure of
preference-based health-related quality of life (HRQL)
[42]) and total 12-month costs calculated based on ser-
vice utilization measured by a modified German version
of the Client Sociodemographic and Service Receipt In-
ventory (CSSRI) [43].
Measurement of effects: EQ–5D-3L and QALY
The EQ–5D-3L consists of five domains measuring
current problems in the dimensions: mobility; self-care;
usual activities; pain/discomfort; and anxiety/depression
[42]. There are three response levels for each domain: 1,
no problems; 2, moderate problems; 3, extreme prob-
lems. Based on the patient’s response, it is possible to
construct a utility score (EQ-5D index score). These util-
ity scores represent preference-based valuations of
HRQL derived from the general population. We used
British [44], instead of German EQ-5D index scores [45]
in this study as the German EQ-5D index scores are in-
fluenced by a major shortcoming. The available German
TTO-based value set was derived in a rather small sam-
ple of the German general population (n = 334). This is
likely to have led to a lack of statistical power in the re-
gression model used to estimate the German value set.
As a result, moderate or severe problems in the dimen-
sion usual activities and moderate problems in the di-
mension anxiety/depression are not associated with a
decrement in the valuation of health states. This results
in substantially higher EQ-5D index scores (total sample
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mean: 0.77 (SD: 0.24)) compared to the British value set
that might not reflect societal preferences. Despite po-
tential cultural differences in preferences for health
states between the German and the British population,
we believe that the British value set is more useful to
value health states in our sample. Additionally, we want
to point out that using the British value set in a non-
UK-based study is a frequently implemented approach
[46–49].
The EQ-5D has been validated in populations with de-
pression [49, 50].
QALY were calculated separately for each period be-
tween time points. These values were summed up to
gain 12-month QALY. The calculation was based on the
assumption that the development of quality of life be-
tween two time points follows a linear trend. This means
that the EQ-5D indices of two following time point, e.g.
T2 and T3, were added and afterwards divided by 2 to
gain the mean HRQL for this period. This mean HRQL
value was multiplied with the observation time of the
specific patient to calculate the QALY.
Questionnaire of service utilization
As there is no official standard for economic evaluations
to inform decision-making in Germany, we adopted the
societal perspective to assess the various effects of the
intervention on healthcare delivery, family support and
productivity. In contrast to the assessment of the other
instruments, we measured service utilization at T0, T2
and T3, not at T1. The questionnaires asked the partici-
pants to recall their service utilization in the preceding
6 months. We considered inpatient services (general hos-
pitals, psychiatric clinics, and rehabilitation clinics), out-
patient physician services (GP + 21 specialists),
outpatient non-physician services (e.g. physiotherapy,
occupational therapy, and exercise therapy), outpatient
psychotherapist services, medication, ambulatory nursing
care and informal care. Additionally, productivity losses
due to sick leave and treatment appointments (absentee-
ism) were assessed. Resource utilization of services in
Step 2 were extracted from the study documentation.
Unit costs
Costs were calculated in Euro at the price level of 2012,
the year the study started. As the time horizon of the
study was 1 year, costs were not discounted.
Detailed information regarding the unit costs is shown
in Table 1. German standardised unit costs developed by
Bock et al. [51] were used for all categories, except for
medication. The monetary valuation of medication was
based on drug codes, dosage and duration and was val-
ued based on the `Rote Liste´, a German pharmaceutical
database [52]. Costs for inpatient services were calcu-
lated on a per day base by hospital type. Outpatient
physician services and outpatient psychotherapist ser-
vices were valued by means of average costs per contact.
Outpatient non-physician services were calculated based
on reimbursement schemes of the German statutory
sickness funds per contact. Ambulatory nursing care
assessed in hours was valued using the reimbursement
schemes of the German statutory sickness funds. Infor-
mal care was valued using the replacement cost method
assuming that a professional caregiver could have
substituted informal care. Thus, the duration of informal
care was valued using the hourly wage rate of workers in
the commercial sector `Social care for older adults and
disabled persons´ [51]. Productivity losses were valued
based on the human capital approach by using mean
gross income plus nonwage labour costs [53].
Intervention costs
Intervention costs were calculated for Step 2 services
only. In steps 1, 3 and 4, outpatient physician or psycho-
therapeutic services, drug prescriptions and inpatient
services were delivered. These costs were assessed and
presented in the specific categories mentioned above.
Table 1 Cost categories and sources of applied unit costs
Sector Service / Goods Units Monetary values (unit costs)
Inpatient services General hospitals, psychiatric hospitals and hospitals for
rehabilitation
Days Type specific mean rates [51]
Outpatient physician services GP, specialists (e.g. cardiologist, internist, ophthalmologist) Contacts Type specific mean rates [51]
Outpatient non-physician
services
e.g. physiotherapy, massage, lymph drainage, ergotherapy Contacts Reimbursement schedule [51]
Outpatient psychotherapist
services
Psychotherapist Contacts Reimbursement schedule [51]
Medication Product Quantity Official pharmaceutical index (Rote Liste) [52]
Nursing care Ambulatory nursing care Hours Type specific wage [51]
Informal care Hours Type specific wage (replacement cost
approach) [51]
Indirect costs Productivity losses Hours Gross income plus nonwage labor costs [53]
Brettschneider et al. BMC Psychiatry          (2020) 20:427 Page 4 of 14
As the intervention in step 2 consists of three services
(bibliotherapy, internet-based self-management, telephone-
administered psychotherapy), intervention costs represent
the sum of costs caused by these three services. Bibliother-
apy was valued by the price of the book (€15). Internet-
based self-management was priced by the license fee of the
self-management program (€250). Usually, the validity of
the license is limited to 6months. If a participant used the
program between baseline and T2 as well between T2 and
T3, we assumed that he or she required two licenses. Costs
for telephone-administered psychotherapy were calculate
by the product of the number of contacts and a price of
€40 per contact. This corresponds to the wage paid to the
psychotherapist per session.
Statistical analysis
Analyses were performed based on the complete sample
(base case analysis) as well as for subgroups of patients
with different depression severity. As we had informa-
tion on the specific ICD-10 diagnosis only in the IG, but
information on the baseline values of the PHQ-9 in IG
and CG, subgroups in the IG and the CG were defined
by the baseline values of the PHQ-9. According to cut-
off values extracted from the literature [54], a score of
5–9 constituted mild depression, a score of 10–14 mod-
erate depression, a score of 15–19 moderately severe de-
pression and a score of 20–27 severe depression. The
subgroup analysis based on severity was defined a priori
in the study protocol [35].
All analyses were performed with STATA 15 (Stata-
Corp, College Station, USA). Results were considered
statistically significant at p ≤ .05.
Imputation of missing values
Missing values were imputed on item level by ‘multiple
imputation using chained equations’ (MICE) by fully con-
ditional specification and based on predictive mean
matching [55–58]. We used sociodemographic character-
istics, comorbidities, disease-specific measures, and health
care utilisation as covariates in the imputation models (in
total: 236 variables either with or without missing values).
The proportion of missing values at baseline ranged from
0% (Age) and 27% (Number of hours absent from work
due to physician appointments). 48% of the participants
(IG: 48%; CG: 49%) had no missing values. Loss to follow-
up was 39% (IG: 40%; CG: 36%).
The imputation was based on sociodemographic, clin-
ical and economic data assessed at baseline as well at T2
and T3 and was performed under fully conditional speci-
fication [58, 59]. Regarding the number of imputations,
we decided to follow the suggestions made by van Buu-
ren [59] and based the number of imputed datasets on
the percentage of missing values in the variable with the
most missing values at baseline (Numbers of hours
absent from work due to physician appointments: 27%).
Therefore, the following analyses are based on 30 data-
sets with N = 737 participants per data set (IG: 569; CG:
168). The results based on each of the imputed datasets
were pooled by applying Rubin’s rules [57].
Comparison of baseline characteristics
We used linear and logistic mixed-effects regression
models to identify baseline differences between IG and
CG. The analyses were unadjusted considering only the
treatment group as independent variable and the pri-
mary practice as random effect.
Comparison of total costs, cost categories and effects after
12 months
The analyses in the complete sample and the subgroups
were adjusted for baseline variables with differences at a
p-value of 0.1. This implies:
Complete sample: Age, employment status, PCS, MCS.
Mild depression: Age, social support.
Moderate depression: Age, employment status, PCS,
MCS, social support, baseline HRQL.
Moderately severe depression: Type of health insur-
ance, depression severity.
Severe depression: baseline HRQL.
Additionally, we considered the specific baseline costs
in all analytical models.
We constructed linear mixed models with the afore-
mentioned covariates as fixed effects and the primary
care practice as random effect. To address the issue of
the skewness of cost data, we calculated bootstrapped
standard errors based on 1000 replications. This number
of replications was frequently applied in recent eco-
nomic evaluations [60–63].
Calculation of the ICER as point estimate of cost-
effectiveness
We calculated the incremental cost effectiveness ratio
(ICER) as a point estimate of cost-effectiveness. The
ICER is a ratio and consists of the differences between
IG and CG in mean total costs (C) in the numerator and







As there is no official German threshold to consider
an ICER cost-effective, we applied the widely used
threshold of €50,000/QALY gained [64].
Calculation of the CEAC as assessment of uncertainty
As the ICER is a point estimate considering only mean
values of costs and effects, it provides no information on
the uncertainty in the analysis. For this reason, we
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constructed cost-effectiveness acceptability curves (CEAC)
based on a series of net-benefit regressions [65, 66].
In a first step, the patient-specific net benefit (NB)
NBi = Ei × λ − Ci was calculated. The NB consists of the
individual 12-month costs in € (Ci), the individual 12-
month effect in QALY (Ei) and a willingness-to-pay
(WTP) margin in €/QALY gained (λ). To construct a
CEAC, the individual NB is used as dependent variable
in a regression model, while group is used as independ-
ent variable. This procedure is repeated for different
WTP margins. In case of our study, we used WTP mar-
gins ranging from €0/QALY gained to €130.000/QALY
gained and proceeded in ‘€10.000/QALY gained’ steps.
To present the CEAC graphically, the different WTP
margins are plotted on the x-axis and the probabilities
of cost-effectiveness are plotted on the y-axis. The prob-
ability of cost-effectiveness at a WTP margin corre-
sponds to the 0.5 x the p-value of the coefficient of the
group difference in the net-benefit regressions in case
the coefficient is negative and 1–0.5 x the p-value if the
coefficient is positive. For a rationale of this approach,
please see Hoch et al. [65].
We used the same regression approach and adjusted
for the same covariates as for the comparison of costs
and effects (step 3).
Results
Characteristics of the study population at baseline
The mean age of the population was 42.9 years (SD: 14.0;
Range: 18–88), the majority was female (73%). The per-
centage of participants living with a partner was 59%. The
mean symptom severity of depression was moderately
severe (mean PHQ-9: 15.0; SD: 4.8). The PHQ-9 identified
93 patients as mildly, 232 as moderately 271 patients as
moderately severe and 141 from as severely depressed.
Mean HRQL (EQ-5D index) was 0.57 (SD: 0.27). Patients
in the IG were more frequently employed than patients in
the CG (IG: 78%; CG: 69%; p < .05). No other differences
reached statistical significance at a level of p ≤ .05
(Table 2).
Complete sample: costs and effects in IG and CG
We found that patients in the IG caused mean total
costs of €23.920 (SD: €28.421), while mean total costs
in the CG were €21.430 (SD: €23.506) (Table 3). The
share of productivity losses in total costs was higher
than that of costs for healthcare and for support by
family in both groups (IG: 60%; CG: 56%). Healthcare
costs cost were mainly caused by inpatient services
(IG: 69%; CG: 70%). The number of QALY over the
course of 12 month was 0.65 (SD: 0.23) in the IG and
0.61 (0.23) in the CG.
Regarding group differences, total costs as well as
healthcare costs, cost for support by the family and
productivity losses were higher in the IG than in the CG
(Table 4). However, these differences did not achieve
statistical significance. Significantly higher costs in the
IG compared to the CG were found for outpatient phys-
ician services (mean: +€467; 95%-CI: [€126;€808]) and
interventional services in step 2 (mean: +€218; [95%-CI:
€196;€266]). Regarding the effects, the IG gained more
QALY than the CG, although on a statistically non-
significant level.
Table 2 Sociodemographic characteristics of the complete sample at baseline
Characteristic Intervention group (n = 569) Control group (n = 168) p-value
Age (years)
mean (SD) 42.09 (13.45) 45.60 (15.45) 0.07
Female: % 72.41 76.19 0.38
Single: % 59.03 56.83 0.64
Private HI: % 5.55 8.73 0.25
Employed: % 77.56 68.53 0.04
Severity of depression (PHQ-9)
mean (SD) 15.29 (4.68) 14.09 (4.91) 0.17
Total costs (€)
mean (SD) 5636 (8297) 7688 (10,764) 0.10
EQ-5D Index
mean (SD) 0.58 (0.26) 0.53 (0.28) 0.22
Physical Health Status (SF-12)
mean (SD) 44.48 (10.52) 42.15 (10.31) 0.06
Mental Health Status (SF-12)
mean (SD) 28.56 (8.41) 30.56 0.07
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Table 3 Mean costs and mean effects per group in the complete sample and subgroups over the course of twelve months (€ 2012)





































Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Total costs (€) 23,920 (28,421) 21,430 (23,
506)
20,228 (27,672) 13,798 (17,
119)
17,729 (22,325) 21,443 (24,
051)
24,647 (29,292) 24,400 (24,
964)
34,425 (32,533) 23,999 (24,
456)




6083 (13,080) 8513 (13,
170)
9346 (17,920) 8859 (15,
794)
12,953 (19,088) 12,149 (18,
559)




3612 (12,111) 6030 (11,
936)
6361 (16,423) 6035 (14,
805)
10,037 (18,413) 9002 (15,
959)
Psychiatric hospital (€) 926 (4927) 1807
(6313)
















Psychiatrist (€) 199 (372) 110 (250) 178 (347) 61 (192) 160 (346) 108 (260) 217 (394) 142 (272) 239 (376) 110 (236)




240 (524) 267 (528) 248 (578) 248 (399) 153 (357) 294 (597) 289 (624) 231 (455) 274 (482) 291 (622)
Drugs (€) 463 (1993) 700 (2172) 887 (3721) 570 (1012) 417 (2024) 517 (781) 446 (1701) 956 (3375) 328 (547) 750 (2297)
Ambulatory care (€) 26 (210) 47 (300) 27 (197) 4 (71) 41 (290) 87 (464) 15 (154) 41 (198) 24 (157) 23 (155)
Intervention in step 2 (€) 196 (279) 0 (0) 253 (309) 0 (0) 179 (265) 0 (0) 197 (285) 0 (0) 188 (265) 0 (0)
Costs of familiy support
Informal care (€) 623 (2952) 607 (2423) 627 (3182) 115 (1101) 257 (1700) 627 (1951) 844 (3569) 867 (3114) 760 (2978) 626 (2802)
Productivity losses (€) 14,342 (17,105) 12,099 (15,
161)
11,026 (15,329) 8324 (12,
141)
11,389 (14,567) 12,303 (15,
551)
14,457 (16,708) 14,674 (17,
023)
20,712 (20,609) 11,224 (13,
383)






































Table 4 Differences in costs and effects in the complete sample and per subgroup (€ 2012)












Mean (€) 95%-CI Mean (€) 95%-CI Mean (€) SE (€)# Mean (€) SE (€)# Mean (€) SE (€)#
Total costs 5016 (−259; 10,290) 9731 (− 3017; 22,478) −628 (−7442; 6186) 6047 (− 3084; 15,178) 14,579* (2785; 26,373)
Healthcare costs 2712 (− 641; 6065) 5966 (− 2568; 14,500) −23 (− 4671; 4625) 3321 (− 1666; 8308) 4324 (− 2982; 11,630)
Inpatient services 1769 (− 1346; 4884) 3468 (− 3589; 10,526) − 453 (− 4889; 3982) 2487 (− 1737; 6712) 2911 (4202; 10,024)
Psychiatric hospital −202 (− 1216; 811) 1101 (− 1649; 3851) −660 (− 2334; 1015) 196 (− 1054; 1445) − 1695 (− 5370; 1980)
Outpatient physician services 467* (126; 808) 723* (134; 1311) 347 (− 120; 815) 832* (338; 1327) 266 (− 365; 896)
Psychiatrist 95* (37; 153) 84 (−65; 234) 79 (−42; 201) 77 (−31; 185) 123 (−36; 281)
Psychotherapist 239 (−37; 515) 250 (− 147; 648) 244 (− 207; 696) 242 (−190; 674) 75 (−533; 683)
Outpatient non-physician services 37 (−59; 132) 46 (−192; 283) −57 (−216; 102) 50 (−97; 197) 51 (−178; 281)
Drugs −43 (−43; 308) 256 (− 565; 1077) 49 (− 304; 402) −199 (− 894; 497) −67 (− 371; 237)
Ambulatory care −8 (−47; 30) 32 (−55; 120) 6 (− 123; 136) −24 (− 87; 40) 124 (−279; 528)
Intervention in step 2 218* (169; 266) 285* (159; 411) 195* (131; 258) 204* (134; 275) 203* (117; 290)
Costs of family support
Informal care 82 (−567; 732) 543 (− 848; 1933) −162 (− 1135; 811) −72 (− 1092; 947) 434 (− 1583; 2450)
Productivity losses 2238 (− 668; 5145) 2754 (− 3438; 8945) − 279 (− 4304; 3744) 1855 (− 4362; 8072) 10,646* (3627; 17,666)







































Subgroups: costs and effects in IG and CG
The total costs in the IG ranged from €17,729 (SD: €22,
325) for patients with moderate depression to €34,245
(SD: €32,533) for those with severe depression (Table 3).
In the CG the range was from €13,798 (SD: €17,119) in
the group with mild depression to €24,400 (SD: €24,964)
in the group with moderately-severe depression. In all
subgroups productivity losses had a larger share in total
costs (range: 55–64%) than costs for healthcare and for
support by the family, except for the CG in the subgroup
with severe depression (47%).
Comparing the development of costs in IG and CG in
the subgroups, we found that mean healthcare costs in
the CG increased with increasing depression severity.
The healthcare costs in the subgroups of patients with
moderate and moderately severe depression were com-
parable, with the exception of drugs. Regarding drugs,
patients with moderately severe depression caused the
highest mean costs of all subgroups.
In the IG, a comparable trend of increasing average
healthcare costs with increasing disease severity can be
observed for patient with moderate, moderately severe
and severe depression. A special pattern can be observed
in the subgroup of patients with mild depression. In
comparison to patients with moderate depression, these
patients caused higher mean healthcare costs (€8576 vs.
€6083), mean costs for inpatient services (€5583 vs.
€3612) and mean drug costs (€887 vs. €417). Of particu-
lar note is that the subgroup with mild depression
caused the highest mean drug costs and mean costs for
psychiatric inpatient services of all subgroups.
In the subgroups, patients in the IG with mild (mean:
+€723; 95%-CI: [€134;€1311]); or moderately severe
(mean: +€832; 95%-CI: [€338;€1327]) depression caused
higher costs for outpatient physician services than those
in the CG. The group of patients with moderate depres-
sion showed no significant cost differences. However,
the total costs in the subgroup with moderate depression
were lower in the IG compared to the CG, yet at a non-
significant level (mean: -€628; 95%-CI: [−€7442;€6186]).
In the group of patients with severe depression, total
costs (mean: +€14,579; 95%-CI: €2785;€26,373]) and
productivity losses (mean: +€10,646; 95%-CI: [€3627;€17,
666]) were significantly higher in the IG than in the CG.
The difference in productivity losses was mainly caused
by significantly higher costs in the IG compared to the
CG between baseline and T2, i.e. in the first 6 months
(mean: +€7593; 95%-CI: [€2142;€13,044]). There were
no significant QALY differences between IG and CG in
the subgroups.
Point estimates of cost-effectiveness
In the complete sample, the ICER was unfavourable
(€627,000/QALY gained). In the group with mild
depression, the IG was dominated by the CG which
means that the IG caused higher costs but gained fewer
QALY than the CG. In the group with moderate depres-
sion, the IG was dominant as costs were lower and ef-
fects were higher than in the CG. In the remaining
groups there were unfavourable ICER of €465,154/
QALY gained (moderately severe depression) and €2082,
714/QALY gained (severe depression).
Uncertainty analyses of cost-effectiveness
Figure 1 shows the CEAC for the different groups. The
CEACs show three different patterns.
Pattern one (complete sample and severe depression)
shows a rather flat slope on a very low level of probabil-
ity for cost-effectiveness. This indicates that the prob-
ability that IG is cost-effective compared to CG is low
for all possible WTP values. Regarding the subgroup of
patients with severe depression, the probability of cost-
effectiveness of IG compared to CG was 2.5% at the
WTP margin of €50.000/QALY gained. By implication,
this means that the CG has a 97.5% probability of being
cost-effective, which meets the margin of error of the
statistical test and hence is an indicator that CG is cost-
effective in the group of patients with severe depression.
The second pattern (mild and moderately severe depres-
sion) shows also a rather low probability of cost-
effectiveness of the intervention (between 10 and 30%).
As a third pattern, the group with moderate depression
shows an already elevated probability of 57% at the mini-
mum WTP, which increases to 78%. Using the WTP
margin of €50,000/QALY gained, the CEAC indicates a
70% probability of cost-effectiveness of the intervention.
Discussion
Our analysis failed to provide sufficient evidence that
the intervention in the IG is cost-effective. In case of se-
vere depression, the evidence represented by the CEAC
even indicates that treatment as usual is preferable from
an economic point of view. As the conclusiveness of this
statement might not be easily comprehensible for
readers not familiar with the interpretation of the CEAC,
we want to explain this. We constructed the CEAC by
the NMB regression approach. As we wanted to indicate
the probability of cost-effectiveness of the intervention
in the IG, we coded TAU as 0 (reference group) and the
intervention as 1. As we considered only two groups in
this regression, the probability of TAU being cost-
effective is the counter-probability of intervention in the
IG being cost effective. Hence, if this probability is 2.5%,
the probability of TAU being cost-effective is 97.5%. In
our analyses the margin of error was set to α = .05. As
the CEAC is a one-sided test a probability of ≥97.5% can
be considered as conclusive. This means we can say that
TAU is cost-effective in this subgroup. These results are
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not in line with the findings by Härter et al., who ob-
served for patients in the IG a pronounced improvement
of symptom burden as well as increased odds of re-
sponse and remission [34]. Nevertheless, in the IG some
indicators for an impact of the intervention on health-
care delivery can be identified.
There are two significant observation that suggest the
existence of such effects. First, the National Clinical
Practice Guideline recommends low intensity treatments
for patients with mild depression [10]. In our study,
these interventional measures (bibliotherapy, web-based
self-management, telephone psychotherapy) showed the
highest costs and incremental costs in this group of pa-
tients in comparison to other degrees of depression se-
verity. Second, the National Clinical Practice Guideline
lays a strong emphasis on treatment in the outpatient
sector by mental health professionals [10]. In the
complete sample, we found that the costs for psychiatric
outpatient services were significantly higher in the IG
than in the CG. The same trend was found for all sub-
groups and the psychotherapeutic services. This can be
interpreted as in line with the National Clinical Practice
Guideline [10]. Additionally, we found the same trend of
increasing costs with increasing depression severity, at
least for moderate, moderately severe and severe depres-
sion. For outpatient mental health services there were
also higher costs in the IG compared to the CG in all
three subgroups. The National Clinical Practice Guide-
line is built on the idea that patients should receive
treatment at an intensity level that matches the demands
caused by the disease [10]. Hence, even if we assume
that the GP in the CG are aware of at least some recom-
mendations of the National Clinical Practice Guideline
and that this influences the increasing treatment inten-
sity in the CG, the existence of the same trend and the,
partially non-significant, higher costs for outpatient
mental health services in the IG can cautiously be seen
as an indicator for the influence of the improved know-
ledge of the National Clinical Practice Guideline and the
intervention.
However, some results in the subgroup of mild depres-
sion deserve special attention. In the interpretation of
these unexpected findings, we have to keep in mind that
this subgroups was rather small (n = 93). The healthcare
costs in this subgroup were much, yet not significantly,
higher in the IG than in the CG. Apart from general
hospital services, there were higher costs for mental
health specific services (inpatient psychiatric, psychiatrist
and psychotherapist services) as well as for drugs in the
IG compared to the CG. The National Clinical Practice
Guideline recommends for these patients watchful wait-
ing and low threshold interventions, like those in step 2.
As these services were often utilized in this group, the
National Clinical Practice Guideline recommendations
seem to have been effective. However, it might have
been the case that GP in the IG by having better access
to psychotherapist services (e.g. by the online platform
for vacant therapy places) brought mild patients into
Fig. 1 Cost-effectiveness acceptability curves for the complete sample and the subgroups by depression severity
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treatment that they were not intended to receive based
on the National Clinical Practice Guideline. That would
mean, that we might have observed a disincentive in this
group, which resulted in an overutilization of services. If
this is the case we identified a misallocation that could
be caused for example by an inefficient education or by
altruistic acts.
Comparing our results to the results of previous stud-
ies is -as shown in the Background- limited by the di-
verse and partially even highly specific nature of these
analyses. Even a comparison to the study conducted by
Simon et al., who treated patients with depression in a
primary care setting, is limited by the facts that the au-
thors (a) only included patients with depression persist-
ent after 6–8 weeks of antidepressant treatment and (b)
used depression-free days at outcome measure [31]. This
reduces the comparability of the results to a high extent.
Hence, we only refer to the studies of Yan et al. and
Meeuwissen at al [32, 33]. In these studies the stepped
care approach was used for treatment of depression in
general in the adult population in a primary care setting.
Their results diverge from our results. Meeuwissen et al.
concluded that stepped care was cost-effective at a high
probability [33] while Yan et al. identified a potential for
cost savings [32]. As highlighted in the review by van
Straten et al., there are often differences in the charac-
teristics of the stepped care approaches [14]. This could
be an explanation for the differences in results between
the study by Yan et al. and our study. Yan et al. evalu-
ated a two-step program considering patients with a
PHQ-9 score of 10 and higher and treated patients with
moderate depression (PHQ-9 score: 10–14) by watchful
waiting and self-management, and patients moderately
severe or severe depression (PHQ-9 score: 15–27) with
more intense treatments [32]. We evaluated a four-step
program considering patients with a PHQ-9 score of 5
and higher, and treated patients with mild depression
(PHQ-9 score: 5–9) by watchful waiting and low-
intensity interventions, patients with a moderate depres-
sion (PHQ-9 score: 10–14) with outpatient pharmaco-
therapy or psychotherapy and patients with moderately
severe or severe depression (PHQ-9 score: 15–27) with
pharmaco- and psychotherapy in an outpatient or even
inpatient setting. Hence, in comparison to Yan et al. we
have treated patients already at a lower disease severity
and treated them with more intensity at an earlier stage
of disease. This means that our intervention had a
higher intensity and could have caused extra costs in
comparison to cost savings. The differences to Meeuwis-
sen et al. might be explained by methodological differ-
ences. This group evaluated a stepped care approach
based on the Dutch Multidisciplinary Guideline for De-
pression by conducting a model-based study based on a
Dutch disease model [33]. We conducted a trial-based
study situated in the catchment area of Hamburg,
Germany. As the German healthcare system shows only
a low level of service integration and is characterized by
prolonged waiting periods for psychotherapy [67], our
intervention, which is based on cooperation and swift
adaption to new circumstances, needed to adapt the
traditional service routines. Over the course of 1 year,
the loss due to efforts of adaption might have been too
large to be offset by gains of efficiency. As a model-
based study is not faced with these issues of implemen-
tation, we might conclude that the study by Meeuwissen
et al. [33] represents the cost-effectiveness of a well-
established and fully integrated stepped care programme,
while our trial-based study might be influenced by im-
plementation effects.
Considering the aforementioned aspect of the study,
we can identify the time horizon of 1 year as the first
limitation of this study. Besides the implementation ef-
fects we might have assesses, long-term effects of the
intervention were not observed. Due to the natural
course of depression, the duration and number of epi-
sodes, the duration of remission and the risk of relapses,
1 year might be too short to observe all differences be-
tween the interventions [68, 69]. It is possible that the
intervention by reducing the risk of relapses or duration
of episodes might even has an impact on the reported
negative effects of a high mental health burden on phys-
ical health [3, 70]. This could have an influence on the
healthcare costs. The second potential limitation is the
effect measure. Härter et al. showed that the interven-
tion reduces symptom severity, leads to more remissions,
and improves the physical health status (measure by the
PCS of the SF-12), while the mental health status (MCS
of the SF-12) remained unaffected [34]. We found no
difference in QALY between IG and CG. There are two
possible explanations. First, as QALY are based on
HRQL, it could be the case that the changes in symptom
severity might not have been strong enough to affect
HRQL [40, 41]. Second, as we used the three level ver-
sion of the EQ-5D to measure HRQL, it is possible to
explain the absence of a difference in effects between IG
and CG by the reduced responsiveness (sensitivity to
change) of the EQ-5D-3L [71, 72]. An additional limita-
tion resulting for the choice of the EQ-5D-3L is that this
analysis is based on QALY. We are aware that there
might have been other outcome parameters in this study
that could have been used, like the PCS, the MCS or the
PHQ-9. We did not consider these potential endpoints
for two reasons. First, the pre-specified analytical con-
cept determined QALY as endpoint of the analysis. Sec-
ond, while there are commonly accepted willingness-to-
pay thresholds for the ICER presented as cost per
QALY, there are no thresholds for the ICER presented
as cost per point of the PCS/MCS/PHQ-9. Next, we
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have to indicate a methodological limitation regarding
our subgroup analyses. GP in the IG determined specific
depression diagnoses based on the ICD-10 criteria and
recommended an initial treatment based on the degree
of severity of the ICD-10 diagnosis. As ICD-10 diagnoses
were not determined in the CG, we were not able to use
these diagnoses to classify patients into subgroups. Con-
sequently, we used the PHQ-9 to categorize patients.
This decision means that some patients were treated in
a way that diverged from the way they were analysed.
This does not affect the analysis of the complete sample,
but could have led to a bias in our subgroup analyses
that cannot be completely quantified. To get an idea of
the potential of the bias, we compared the patients who
were consistently diagnosed by both approaches to those
who were categorized in different groups (data not
shown). We found no noticeable differences in costs, es-
pecially healthcare costs. For example, in the group of
patients with mild depression (consistent diagnoses
made by the PHQ-9 and ICD-10) the cost were still
higher than for those cases who were diagnosed as mild
by the PHQ-9 and as moderate or severe based on the
ICD-10 criteria. Additionally, the treatment costs for
consistently diagnosed mildly depressed patients were
still higher than those for the consistently moderately
depressed patients. This noticeable finding appears to be
stable to a certain degree.
Furthermore, we have to consider that the use of pa-
tient questionnaires is associated with a risk of missing
values and recall bias. The degree of missing values was
manageable and was handled by an elaborated approach
[55–58]. The presence of a recall bias, which could have
been unbalanced between the groups, cannot be ruled
out or controlled. Additionally, in the interpretation of
the results, we have to keep in mind that the
randomization was not stratified for the subgroups. This
means that the composition of the subgroups was not
necessarily evenly allocated. For this reason, we adjusted
the analyses in the subgroups for the group specific sig-
nificant baseline differences.
Conclusion
We found no evidence that our intervention is cost-
effective over a one-year period. However, as there is
evidence that guideline-based stepped care approaches
for the treatment of depression can be cost-effective, we
do not want to rule out that an adapted version of our
intervention could be cost-effective. Consequently, there
is further research needed to adapt our intervention and
to develop implementation strategies that make cost-
effective service delivery possible.
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